Ranbaxy recalls two lots of generic Lipitor in U.S.

The action was taken after a complaint by a pharmacist who discovered a 20 mg tablet inside a sealed bottle of Atorvastatin 10 mg tablets.

March 08, 2014 08:01 pm | Updated November 17, 2021 05:35 am IST - New Delhi:

Ranbaxy Laboratories, which is reeling under regulatory action from the U.S. Food and Drug Administration (USFDA), has recalled more than 64,000 bottles of Atorvastatin calcium tablets, a generic version of cholesterol-lowering drug Lipitor, as some bottles could possibly contain a higher dose.

Voluntary recall “Ranbaxy Pharmaceuticals is conducting a voluntary recall in the U.S. limited to two lots of Atorvastatin calcium tablets, 10 mg manufactured in India, which expire in May, 2014,” the drug maker said in a statement.

Complaint The action was taken after a complaint by a pharmacist, who discovered a 20 mg tablet inside a sealed bottle of Atorvastatin 10 mg tablets.

A Ranbaxy spokesperson stated the actual recall had happened in January.

Ranbaxy, majority of which is owned by Japan’s Daiichi Sankyo, said it recalled the tablets “because of a remote possibility of the presence of a 20 mg Atorvastatin calcium tablet in a 10 mg bottle. This is the basis of the voluntary recall.”

It also added that to date, the company has not received any product complaints related to these batches.

Additionally, other lot numbers, package sizes and strengths are not affected by this recall, which is being conducted at the retail level.

“Ranbaxy is proactively recalling the lots out of an abundance of caution, keeping the safety of its patients in mind and with the full knowledge of the USFDA,” it added.

In January, the USFDA had prohibited Ranbaxy from producing and distributing drugs for the American market from its Toansa facility in Punjab. This was the company’s fourth plant to face regulatory action from the U.S. food regulator, after Mohali, Paonta Sahib and Dewas plants.

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.